Compliance Tip of the Day: Trust and Verify
Compliance Tip of the Day: AI Assistant for Compliance
Compliance Tip of the Day: Costs and Benefits of AI
(Podcast) The Briefing: Who Owns What – Understanding Copyright in Collaborative Projects
Fox on Podcasting: Mastering Content Creation and Personal Branding with Dave Polykoff
Compliance Tip of the Day: How a CFO Views Compliance and Risk
Nonprofit Basics: Grant Agreements—Matching Grants, IP, Recoverable Grants & More
Compliance Tip of the Day - Extending Compliance Value Across Your Organization
AI Today in 5: August 12, 2025, The Creating Billionaires Episode
Adventures in Compliance: The Novels - The Valley of Fear, Sherlock Holmes’ Investigative Techniques for Today’s Challenges
8 Key Takeaways | Strategies to Drive Influence With and Without Authority
Moving Beyond the Usual Helpline Data
Nonprofit Basics: Grant Agreement Best Practices
From Forest to Fortune: Navigating Workplace Ethics With Robin Hood — Hiring to Firing Podcast
Adventures in Compliance: The Novels - The Valley of Fear, Introduction and Compliance Lessons Learned
[LEGAL MARKETING MOMENTS] A Simple Tip to Master Generative AI Prompts
FCPA Compliance Report: 10 Core Principles for Effective Internal Investigations with Michelle Peirce
Avoiding a Bored Board
Compliance Tip of the Day: Crowd Sourcing Risk Intelligence
Great Women in Compliance: The Compliance Influencer with Bettina Palazzo
AGG partner and Life Science team member, Allison Raley, will present a complimentary webinar examining how life sciences companies can overcome challenges in the face of U.S. tariffs. As international trade tensions persist...more
Join the conference that the “who’s who” of Hatch-Waxman litigators have designated as the forum which sets the standards for Paragraph IV practice. ACI’s Paragraph IV Litigation Conference is returning LIVE & IN-PERSON to...more
Last week, the Food and Drug Administration (“FDA”) issued a pair of Guidance for Industry documents outlining best practices for developing proprietary names (i.e. brand names) for prescription and nonprescription human drug...more
Hear from the FDA and the leaders of the biosimilars and innovator biologics industries about the impact of the pandemic on the global IP market and gain practical guidance for what is coming down the pipeline. The novel...more
China is cautiously recovering from the peak of the COVID-19 outbreak and is moving into a new period of investor-friendly policies aimed at restarting China’s economic engine....more
U.S. and international health authorities continue to respond to the outbreak of the novel coronavirus (COVID-19). While originally detected in Wuhan City, Hubei Province, China, as of the date of this alert the virus has now...more